The call, on record
MRNA bullish call
Target Price
$300
Quoted text as recorded“And it could also go great and it's a $300 stock.”@ 12:47 · open at this moment on YouTube ↗
Our interpretation
- Source published
- Oct 20, 2026
- Timeframe
- Conditional on a successful presentation this Saturday, October 24; no explicit price deadline.
- Stored reference price
- $226.89
- Latest provider quote
- $258.38As of Nov 4, 2026, 9:00 PM UTC. May be delayed; does not resolve this call.
- Interpreted confidence
- low
- Specificity
- specific
Email me when this call is scored
We’ll email you the result of this call and of the other tracked MRNA calls as they resolve. No account needed.
Used only for these updates. Privacy
Our summary of the thesis
BullishStructured interpretation of the video, not a verbatim quotation. Check the source for conditions, emphasis and context.
The host is enthusiastic about Moderna's personalized cancer therapy and the potential for AI to accelerate treatment development and broaden access. He presents the October 24 presentation as a major catalyst with sharply different upside and downside outcomes.
Key arguments
- AI can accelerate identification of cancer-specific targets and increase the number of targets used in personalized treatment.
- Faster processing could reduce costs and enable more patients to receive treatment.
- The therapy could potentially expand to additional cancers.
- The upcoming presentation could support renewed investor interest after the decline of Moderna's COVID-related growth.
- The host owns Moderna and describes buying around the $135–$145 area.
Counter-arguments acknowledged
- The presentation could deliver bad news.
- The investment depends heavily on one treatment and carries substantial clinical trial risk.
- A disappointing presentation could erase recent stock gains.
- The $220 target mentioned is Bank of America's target, not an independently adopted host target.
Hedges and caveats (from the video)
- Moderna's presentation could disappoint, causing substantial losses.
- Moderna has concentrated exposure to a single treatment and significant trial risk.
- Tempus AI's reported profit largely reflected stock investment gains rather than underlying operating profitability.
- The host considers it too early to identify Tempus AI as a winner in healthcare data and applications.
- The host discloses exposure to two of the three featured companies and explicitly confirms holding Moderna.
- The discussion is not personalized financial advice.
About this record
Not yet reviewed by a moderatorImported analysis · scheduled AI source. A quote, summary and outcome each need their own context. Moderator review does not certify investment performance.
- Source published
- Oct 20, 2026, 9:26 PM UTC
- First recorded by TubeRank
- Oct 20, 2026, 9:42 PM UTC
- Record last updated
- Oct 20, 2026, 9:42 PM UTC
- Moderator review recorded
- Not recorded
- Transcript provenance
- YouTube captions (manual or automatic)
- Recorded analysis processor/source label
- codex-cli-scheduled
- This can identify a workflow rather than an exact AI model version.
- Submission path version
- manual_v1
- Identifies the precomputed submission path. It does not identify an AI model version or imply human authorship.
- Outcome methodology version
- Not recorded; not audited under current rules
Recent record changes 1 shown
Oct 20, 2026, 9:42 PM UTC
source updated
- Recorded analysis processor/source label
BeforeNot recorded
Aftercodex-cli-scheduled
- Extraction or submission version
BeforeNot recorded
Aftermanual_v1
Showing up to 20 recent changes. The complete feed has 2 recorded events for this call, including its initial entry. Read the full paginated history (JSON); follow nextCursor while hasMore is true.
Why we interpreted the confidence this way
The $300 outcome depends on favorable presentation results and is expressed as a possibility alongside substantial downside.